ANNUAL REPORT 2020 | ACTIVE BIOTECH AB
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Active Biotech's partner Teva starts laquinimod clinical trial
3 Reasons to Buy Teva Right Now - TheStreet
Weekly Biotech Report covering Vantrela by Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) - Market Exclusive
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
CHMP Says No to Teva and Active Biotech's Nerventra | 2014-01-28 | FDANews | FDAnews
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Fortified with sentiment and cash, Active Biotech presses on | Evaluate
Active Biotech and Ipsen to present
PharmaShots | Incisive News in 3 Shots
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva returns laquinimod global rights to Active Biotech
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva takes $215M hit from currency effects
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Teva posts positive phase 3 migraine data, plots FDA submission | Fierce Biotech
Prostate Cancer Therapeutics Market Competitive Landscape
Teva Pharmaceutical Industries Ltd. Active Biotech AB Web Site: www.tevapharm.com Web Site: www.activebiotech.com ______
Laquinimod - Wikipedia
